Abstract
Leukotrienes are important mediators of pain and inflammation and they are produced in the arachidonic acid pathway via 5-lipoxygenase. They have been shown to have important roles in pyresis following antigen attack and in aspirin- intolerant asthma. They promote inflammation processes including eosinophil migration, increase in vascular permeability and bronchoconstriction. Hence, targeting the enzymes involved in the synthesis of these mediators can lead to the development of novel anti-inflammatory drugs. However, no drugs have yet been developed targeting leukotriene C4 synthase, a key enzyme leading to the synthesis of cysteinyl leukotrienes. The recent elucidation of its crystal structure now opens up the possibility of drugs against it. The inhibitors developed for this enzyme until now and the structural features responsible for their activity are discussed in this review. This understanding could lead to the design of new chemical entities.
Keywords: Asthma, anti-inflammatory drugs, inflammation, inhibitors, leukotriene C4 synthase, 5-lipoxygenase, antigen attack, cysteinyl leukotrienes, bronchoconstriction, prostaglandins
Current Drug Targets
Title:Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Volume: 13 Issue: 8
Author(s): Nisha S. Devi and Mukesh Doble
Affiliation:
Keywords: Asthma, anti-inflammatory drugs, inflammation, inhibitors, leukotriene C4 synthase, 5-lipoxygenase, antigen attack, cysteinyl leukotrienes, bronchoconstriction, prostaglandins
Abstract: Leukotrienes are important mediators of pain and inflammation and they are produced in the arachidonic acid pathway via 5-lipoxygenase. They have been shown to have important roles in pyresis following antigen attack and in aspirin- intolerant asthma. They promote inflammation processes including eosinophil migration, increase in vascular permeability and bronchoconstriction. Hence, targeting the enzymes involved in the synthesis of these mediators can lead to the development of novel anti-inflammatory drugs. However, no drugs have yet been developed targeting leukotriene C4 synthase, a key enzyme leading to the synthesis of cysteinyl leukotrienes. The recent elucidation of its crystal structure now opens up the possibility of drugs against it. The inhibitors developed for this enzyme until now and the structural features responsible for their activity are discussed in this review. This understanding could lead to the design of new chemical entities.
Export Options
About this article
Cite this article as:
S. Devi Nisha and Doble Mukesh, Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation, Current Drug Targets 2012; 13 (8) . https://dx.doi.org/10.2174/138945012802009053
DOI https://dx.doi.org/10.2174/138945012802009053 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessment of Airway Inflammation by Exhaled Breath Condensate and Impedance Due to Gastroesophageal Reflux Disease (GERD)
Inflammation & Allergy - Drug Targets (Discontinued) Transcription Factors in Asthma: Are Transcription Factors a New Target for Asthma Therapy?
Current Drug Targets Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Subject Index Volume 2
Current Pediatric Reviews Patent Selections:
Recent Patents on Materials Science Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets Chronopharmaceuticals: Hype or Future of Pharmaceutics
Current Pharmaceutical Design Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Chemical and Physical Aspects of the Edible Fractions and Seeds of Jamelao (Syzygium cumini, L. Skeels)
The Natural Products Journal Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Assessment of Prescription Pattern in Asthma Therapy at Shamli Hospitals
Reviews on Recent Clinical Trials Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience
Current Pharmaceutical Design Anti-Allergic Action of Glucocorticoids: Comparison with Immunosuppressive and Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protein Interaction Networks in Metallo Proteins and Docking Approaches of Metallic Compounds with TIMP and MMP in Control of MAPK Pathway
Letters in Drug Design & Discovery Toxic Metals in Herbal Medicines. A Review
Current Bioactive Compounds Many Drugs and Phytochemicals Can Be Activated to Biological Reactive Intermediates
Current Drug Metabolism Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets